Elanco is executing a turnaround marked by accelerating revenue growth (10.2% in Q2 2026) and a 1,180 basis point gross margin expansion to 58.3%, driven by a favorable product mix and cost discipline. The balance sheet is deleveraging, with debt-to-equity imp...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth accelerated to 10.2% in Q2 2026 with gross margin expanding to 58.3% from 46.5% a year earlier, though SG&A remains elevated at 32.8% of revenue.
Elanco's latest quarterly results and initial 2026 guidance have improved investor sentiment, highlighting operational execution and margin expansion.
Elanco is the second largest independent animal health player in a growing market, with a strong presence in both farm animals and pets.
The company has a late-stage pipeline with potential blockbuster products expected to launch in large market spaces, driving future growth.
Trailing total returns as of 9/25/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 5, 2026 | $0.34+26.3% vs $0.27 | $1.4B+4.2% vs $1.3B |
Q2 2026 May 6, 2026 | $0.40+15.7% vs $0.35 | $1.4B+7.4% vs $1.3B |
Q1 2026 Feb 24, 2026 | $0.13+18.2% vs $0.11 | $1.1B+4.7% vs $1.1B |
Q4 2025 Nov 5, 2025 | $0.19+46.2% vs $0.13 | $1.1B+4.1% vs $1.1B |
Elanco Animal Health (NYSE: ELAN - Get Free Report) and Amarin (NASDAQ: AMRN - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings. Volatility and Risk Elanco Animal Health has a
Corient Private Wealth LP lifted its position in shares of Elanco Animal Health Incorporated (NYSE: ELAN) by 124.1% during the undefined quarter, according to its most recent disclosure with the SEC. The firm owned 342,271 shares of the company's stock after buying an additional 189,540 shares during the period. Corient Private Wealth LP
INDIANAPOLIS, Sept. 17, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will attend the BofA Securities Global Healthcare Conference 2026 on September 22, 2026.
Elanco Animal Health Incorporated (ELAN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Benchmark ELAN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Elanco Animal Health Incorporated (ELAN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $22.37 | $11.17B | -47.59 | 6.22% | -4.92% | -3.67% | — | |
| $70.31 | $29.48B | 11.68 | 2.28% | 27.49% | 69.25% | — | |
| $25.56 | $1.01B | 159.75 | 3.63% | 1.96% | 2.13% | — | |
| $33.93 | $1.38B | 28.51 | 27.37% | 6.57% | 28.67% | — | |
| $13.66 | $2.97B | -341.50 | -2.71% | -0.91% | -0.37% | — | |
| $1.56 | $33.23M | -0.57 | -21.13% | -17.34% | -91.67% | — |
Elanco Animal Health Incorporated (ELAN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Elanco Animal Health Incorporated (ELAN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
May 27, 2026·SEC
May 6, 2026·SEC
Get notified when ELAN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Elanco Animal Health Incorporated (ELAN) stock FAQ — growth, dividends, profitability & financials explained
Elanco Animal Health Incorporated (ELAN) reported $5.02B in revenue for fiscal year 2025. This represents a 72% increase from $2.91B in 2016.
Elanco Animal Health Incorporated (ELAN) grew revenue by 6.2% over the past year. This is steady growth.
Elanco Animal Health Incorporated (ELAN) reported a net loss of $199.0M for fiscal year 2025.
Elanco Animal Health Incorporated (ELAN) has a return on equity (ROE) of -3.7%. Negative ROE indicates the company is unprofitable.
Elanco Animal Health Incorporated (ELAN) generated $379.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
